Member Info for TorquayFan

Yes Cleaner, IMO a Vax weary World would even now be attracted to a 'Universal' covid vaccine. I'll be up for the Pfizer + 1 newbie as my 2nd booster, when it becomes available soon.

Covid is still around - my Cousin's 69 year old Husband died a few weeks ago from Covid. They had known each other since they were 14 ! There's still a place for a good vaccine for sure.

203 now - including me ! That's 34 per month on average in a Nation of 60,000,000 . . . . .
I'm guessing Scancell LTH are significant contributors to that number.
What could the increasing numbers mean ?
IMO very little. A red herring ? But I hope to be wrong.
I could only 'like' once . . . . . Come on Scancell !!!

Johnny - yes I was commenting on the issue of 'likes'. And I do hope you are right about the point having some significance and that I am wrong. With a similar average to you and with the SP at a measly 12.6 pence, I too could do with some cheering up ! After 11 years !

Referring to Bermuda's clarity on the timelines for data on Covidity, I would just add that on the wider front, Scancell have before turned up with surprise NEWS, so let's hope for some more of that.

Have good Sunday. ATB

Johnny - as always I read your posts carefully but my immediate impression was that you might be looking at the wrong tree this time and making something of rather a little, (on this occasion only). BUT I could be wrong - it happens often enough. Maybe it's SCLP LTH clocking in to see what you are posting about ? Well done for trying and I hope you are right. ATB

Thanks for that Bermuda - a clear explanation.

Crikey Cleaner - the 'Morning Star' ?
I'm surprised it's still going !

And !! Let's wish this Patient the very best of progress with a ModiFY recovery in full !!

Great minds LOL

Rich - IMHO it doesn't matter. Maybe they just fired the RNS as soon as the 'data' was confirmed, without waiting for tomorrow 7am. More please . . . . .

Thanks GF

First patient dosed in Cohort 2 of the ModiFY

Tue, 16th Aug 2022 14:00
RNS Number : 2138W
Scancell Holdings Plc
16 August 2022


16 August 2022



Scancell Holdings plc

("Scancell" or the "Company")



First patient dosed in Cohort 2 of the ModiFY Phase 1 clinical trial



Well tolerated safety profile seen with Modi-1 at the starting dose in the first-in-human clinical trial



Further safety and immunogenicity data expected to be available in H2 2022



Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that the first patient in Cohort 2 of the multicentre Phase 1 Modi-1 clinical trial (ModiFY) has been enroled and dosed. The dosing follows approval of the dose escalation by the Safety Review Board. The ModiFY study is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. In the trial, Modi-1 will be administered alone or in combination with checkpoint inhibitors (CPIs) in patients with head and neck, triple negative breast and renal tumours.



Modi-1 is the first candidate of Scancell's Moditope® platform. This open label study will recruit up to 125 patients in up to 20 clinical trial sites across the UK. The objective for Cohort 1 of the trial was to assess the safety of the two citrullinated vimentin peptides at a low starting dose. All three patients have successfully received two doses; the injections were well tolerated with no safety concerns. Patients in Cohort 2 will receive a higher dose of both the two citrullinated vimentin peptides plus a citrullinated enolase peptide.



Modi-1 peptides are linked to AMPLIVANT®, a potent adjuvant which enhanced the immune response 10-100 fold and resulted in highly efficient tumour clearance, including protection against tumour recurrence, in preclinical models. AMPLIVANT® is the subject of a worldwide licensing and collaboration agreement with ISA Pharmaceuticals for the manufacturing, development and commercialisation of Modi-1.



The Company expects further safety and immunogenicity data to be available in H2 2022 and early efficacy data in 2023.



Further information relating to the clinical trial can be found on the Company's website at www.scancell.co.uk and at https://clinicaltrials.gov



Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "This is a significant safety milestone for the Company, being the first time a citrullinated peptide vaccine from our Moditope® platform has been given to cancer patients. We are encourgared that there were no safety concerns in the initial cohort, allowing us to proceed smoothly with the dose escalation."



This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

Listened again to Prof. Anthony Hardern, Deputy Chair of the JCVI on R4. He observed that in the future other Companies will surely come up with bi-valent or multi-valent vaccines, but no mention of a 'Universal' . . . . AZ is now apparently sidelined and Moderna bv and Pfizer/BioNTech will be offered this winter.

Moderna UK admitted there is little or no working experience with the bi-valent although it's been fully approved.

On a personal note, I'm ready for my 4th (2nd booster) in September and will be opting for Pfizer because my 1st booster, a 50% aspirated shot of Moderna, knocked me about unpleasantly for 24 hours.

As Covidity is not yet available, (wink), that'll have to do for now. GLA

Cleaner nice link - reads like the piece I saw earlier. Thanks.
Ray an interesting observation about Prof Lindy and 'her' T-cells.
I wonder what will, (rather than might), come out of all this, one day.

No Ruck. I wasn't getting 'carried away'. Your words.

Thanks Bermuda. Fairly put but if BioNTech can observe that there is better science and a better potential vax product available, I am quite certain that it is a possibility that they, or any other Company for that matter, might consider changing strategy IF the advantages of doing so were obvious enough. I'd also think Pfizer might jump with them IF the data was good enough.

The stakes for a possibly more universal Covid vax are the very highest. I'm not getting carried away (Ruck), but it is a possibility.

I enjoyed your comments about how much the Covidity research has helped the wider Scancell cause.

ATB

Ruck - I thought I had raised the point quietly enough. I'm not getting 'carried away' ! But I hadn't noticed TD describing BioNTech as a 'prior collaborator' and that's interesting and maybe a little disappointing.

Ivy thanks - Cleaner's link shows that BioNTech do some manufacturing. In their relationship with Pfizer, I'd be surprised if BioNTech were not at least controlling the manufacture as part of their deal simply because BioNTech are the masters of the science for that vax.

We'll see - news coming ! But so is Christmas . . . . .

Cleaner/ WTP - I recently read about that new Pfizer/BioNTech vax - it seemed to focus on wider coverage of 'Omicron' only. What puzzles me - there is a close relationship between BioNTech and Scancell - they know what Covidity is about. With the importance of Covid in mind I would have expected BioNTech to get involved. I mean, there's no time to lose on this front is there? Maybe the BioNTech powers that be don't rate the Covidity project or they feel the 'nih' factor - (not invented here).

Let's hope we get an update soon . . .

Ivy you're quite the 'Author' - nice post. Your concluding para makes me think of this again, posted yesterday - "I'm noting that Richard Goodfellow is still 'interim' Chief Business Officer. 'Interim' is normally temporary or provisional but Richard now appears . . . . . to be permanent ! "

Ray of course we're all looking forwards and the arrival of Redmile was key. But Scancell's lack of progress with deals over the last 11 years has been 'trying' to say the least. However, with little other real choice, as always, I shall have to wait and see and continue to play 'tick tock'. Nil desperandum.

Q3 and Q4 will hopefully be abundant with news . . . . . . . .

"Future-proofing the world against COVID-19 and other coronaviruses"

"Covid-19 is on the march once again, with an increasing number of infections around the world caused by the Omicron subvariants known as BA.4 and BA.5. What makes these subvariants different from the others that have emerged over the past few years? In these subvariants the Spike protein, the part of the virus that latches on to and enables it to invade cells, has mutated in such a way that it reduces our immune system’s ability to identify it and prevent infection. From a viral perspective that means it is better adapted to evade the immunity of people who have been infected, vaccinated, or both.

We’re seeing the impact of such adaptation in the recent surge in new infections and re-infections across Europe, UK, and USA, despite high vaccination rates and high rates of previous infection. This relentless emergence of Sars-CoV-2 variants has shown us it is inefficient at best, and futile at worst, to think that we can make vaccines and treatments against each new variant that arises. Essentially, we cannot keep up with the viral changes in a way that is effective in preventing disease.

This is of concern particularly as the governments around the world are doing battle with understandable levels of ‘pandemic fatigue’ within their populations as well as the virus itself. So we need to broaden our scope and our thinking.

The reality is that if the world is to chart a long-term route out of this coronavirus pandemic—and potentially the next coronavirus pandemic—we need to go beyond the ‘one bug, one drug’ mindset that has characterised our current response. We need vaccines that can provide broad protection against multiple variants, and even other coronaviruses that harbour pandemic potential."

https://cepi.net/news_cepi/future-proofing-the-world-against-covid-19-and-other-coronaviruses/l

"The COVID-19 pandemic is not over, as the Omicron variant shows. This means the R&D job is not yet done. Focused investments are still urgently needed in specific areas of vaccine R&D. These include optimizing current vaccines, as well as developing broadly protective or “variant-proof” vaccines against SARS-CoV-2 and, ultimately, broad approaches to the whole coronavirus family.

We’ve seen extraordinary advances in vaccinology over the past couple of years. We need to build on these advances, so we can strengthen our defenses against the virus and stay one step ahead of it. No single organization or country can meet this challenge—it demands a concerted and coordinated global effort.

Multiple safe and effective COVID-19 vaccines are now globally available. But there is still substantial scope to optimize and improve the design and use of these vaccines to maximize their global health impact and their impact in different at-risk populations (such as elderly populations or in people who are immunocompromised) who may respond in different ways to a vaccine.

We can make it easier to deploy vaccines through regimens of single-dose instead of multiple-dose vaccines, especially in countries with transient populations or weaker health systems, or in high-risk environments such as refugee camps. And developing vaccines that don’t require challenging cold-chain requirements would help in low-resource settings that lack this infrastructure."

https://cepi.net/news_cepi/why-the-covid-19-rd-job-is-not-finished/

Chester and all - thanks for the posts. Scancell are indeed nursing a long list of opportunities. But after the announcement that the heroic RG had stepped in, I was expecting a 'permanent' appointment by now - there must be lots of work for the CBO to do !